South Korean Plan To Shorten IND Approvals Raises Competition With Singapore For Clinical Trials Hub
This article was originally published in PharmAsia News
Executive Summary
Patient differences will come into sharper relief in attracting Phase I clinical trials if, as expected, South Korea cuts its IND approval timeline near par with Singapore.